A CAR-T Success Story in China: A Beacon of Hope for Acute Myeloid Leukemia(AML) Patients

A CAR-T Success Story in China: A Beacon of Hope for Acute Myeloid Leukemia(AML) Patients

patient story

#CAR-T #AcuteMyeloidLeukemia #AML #ChinaHealthcare #patientstory #CD33

In the field of cancer treatment, China’s medical advancements have brought new therapeutic opportunities for patients, especially with CAR-T cell therapy. Although CAR-T has achieved significant success in treating lymphoid tumors, its application in myeloid malignancies, particularly acute myeloid leukemia (AML), has been challenging. However, a recent successful case of CD33 CAR-T therapy in China has ignited hope for patients with refractory relapsed AML.

#### Patient Story

The patient is a 25-year-old Chinese male who initially sought medical attention due to dizziness and fatigue. He was eventually diagnosed with high-risk AML associated with the DEK::CAN fusion gene, which has a very poor prognosis. Despite some initial effectiveness of chemotherapy and undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT), the disease relapsed six months later.

After multiple attempts with targeted therapies and donor cell infusions, the results remained unsatisfactory. Just when traditional treatments seemed ineffective and hope was dwindling, the patient sought out my Advanced Medicine in China team.

#### Breakthrough Treatment: China’s CD33 CAR-T

The patient received a consultation and treatment from the medical experts of my Advanced Medicine in China team. After admission and initial preparations, he underwent CD33 CAR-T therapy, an innovative treatment specifically targeting myeloid tumors. After three days of chemotherapy conditioning, the CAR-T cells were infused on day 11. Although there was a mild fever during this period, the patient experienced no significant discomfort. Subsequently, the bone marrow examination revealed astonishing news: leukemia cells had completely disappeared, and the DEK::CAN fusion gene was nearly undetectable, indicating that the disease was in a state of complete remission.

Despite experiencing a lung infection during treatment, the patient’s condition improved after antibiotic therapy. He did not suffer from severe side effects such as persistent cytopenia, and his blood parameters returned to normal. He was ultimately discharged smoothly.

#### Sustained Remission and a Bright Future

Two months after receiving CD33 CAR-T cell therapy, the patient remains in a state of complete molecular remission, with normal blood counts and a significant improvement in quality of life. This case demonstrates that CAR-T therapy not only successfully controlled refractory relapsed AML but also significantly enhanced the patient’s chances of survival and quality of life.

#### A New Chapter for CAR-T Treatment of AML in China

This case highlights China’s innovative capabilities in the field of CAR-T therapy, particularly in the treatment of myeloid malignancies. For AML patients like this young man who have faced multiple treatment failures, China’s CAR-T therapy undoubtedly brings new hope.

Although global CAR-T therapies for myeloid malignancies are still in their infancy, this groundbreaking advancement in China indicates that CAR-T therapy is poised to become a crucial method for treating refractory relapsed AML in the future. As research deepens and technologies mature, this therapy may save more patients in dire circumstances.

China’s leading position in CAR-T treatment is bringing new hope to patients worldwide. For all AML patients, this story proves that the path to a brighter future has been paved, and for many, it begins with China’s CAR-T therapy.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #InnovativeTherapy #PatientSuccess #MedicalAdvancements #HopeInHealthcare #Immunotherapy

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

9 months ago CAR-T

Precision Treatment Journey: Defeating Multiple Myeloma with Chinese CAR-T Therapy

👑🍋Precision Treatment Journey: Defeating Multiple Myeloma with Chinese CAR-T Therapy👑🍋

Multiple Myeloma

 

💪Meet John, a resilient man from New Zealand who has been battling multiple myeloma, a relentless form of cancer. Severe bone pain has confined him to bed for an extended period, disrupting his daily life. However, a glimmer of hope emerged when he sought treatment at Renji Hospital’s Hematology Department in Shanghai, China.

🍒Renji Hospital’s medical team, led by Professor Hou Jian, specializes in CAR-T cell therapy, a revolutionary approach to target cancer cells with precision. John’s journey began eleven years ago when he was diagnosed with multiple myeloma. Despite undergoing numerous chemotherapy sessions and two autologous stem cell transplants, his condition deteriorated rapidly over the past year.

🍈Intense back pain rendered him unable to stand or walk, forcing him into prolonged bed rest and heavy reliance on pain medication. Further assessments revealed widespread extramedullary plasmacytomas in his bones and throat, along with complex chromosomal abnormalities, indicating a grim prognosis.

🍓Having exhausted conventional treatments, John explored alternative options and learned about Renji Hospital’s expertise in CAR-T cell therapy for refractory multiple myeloma. In 2016, Professor Hou Jian’s team initiated clinical trials utilizing CAR-T cell therapy, accumulating significant experience in treating relapsed and refractory cases.

🍇Upon evaluation, John’s medical team identified substantial tumor burden and compromised bone marrow function due to extensive chemotherapy. Despite the challenges, Professor Hou Jian’s team tailored a personalized treatment plan, opting for dual CAR-T therapy targeting CD19 and BCMA antigens.

🥑John has since returned to New Zealand and maintains regular contact with his medical team at Renji Hospital. Ongoing monitoring and follow-ups ensure his progress is closely tracked. “John is gradually reclaiming his daily life. Recently, he even shared photos of hiking and fishing adventures with us,” Professor Hou Jian shared.

🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

 

#CARTtherapy #MultipleMyeloma #PrecisionTreatment #RenjiHospital #HopeInHealthcare #CART #cancer #cancertreatment #medicaltourism #tuomor #cartcell #CARTtherapy